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We report 2 families with undiagnosed recessive pre-
synaptic congenital myasthenic syndrome (CMS).
Whole exome or genome sequencing identified segre-
gating homozygous variants in VAMP1: c.51_
64delAGGTGGGGGTCCCC in a Kuwaiti family and
c.146G>C in an Israeli family. VAMP1 is crucial for vesi-
cle fusion at presynaptic neuromuscular junction (NMJ).
Electrodiagnostic examination showed severely low com-
pound muscle action potentials and presynaptic impair-
ment. We assessed the effect of the nonsense mutation
on mRNA levels and evaluated the NMJ transmission in
VAMP1lew/lew mice, observing neurophysiological fea-
tures of presynaptic impairment, similar to the patients.
Taken together, our findings highlight VAMP1 homozy-
gous mutations as a cause of presynaptic CMS.
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The congenital myasthenic syndromes (CMSs) are aheterogeneous group of inherited diseases of the neu-
romuscular junction (NMJ), with fatigable muscle weak-
ness as the clinical hallmark.1 Several molecular causes
can be implicated in CMS pathophysiology, including
mutations in genes encoding proteins associated with the
muscle nicotinic acetylcholine receptor and the synaptic
basal lamina, or (more rarely) involved in the NMJ pre-
synaptic transmission.2–6
We describe 2 families from Kuwait and Israel
where 2 of the siblings in each family presented clinical
and neurophysiological features typical of a presynaptic
CMS. Whole exome sequencing (WES) or whole
genome sequencing (WGS) followed by Sanger sequenc-
ing unraveled either a homozygous frameshift or missense
variants in VAMP1 segregating with the phenotype in the
2 families. Screening a cohort of 63 undiagnosed CMS
individuals failed to show any further causative variant in
VAMP1.
Materials and Methods
Subjects
This study was approved by the institutional review boards of
the participating centers. Informed consent was obtained from
the families. Clinical details were obtained from medical
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records. Neurophysiological studies were performed according
to standard procedures.7,8
Genetic Studies
Before WES, the Kuwaiti probands (Family 1) underwent exten-
sive molecular investigations that included sequencing of AGRN,
mitochondrial DNA (mtDNA) sequencing, and deletion/duplica-
tion analysis and array comparative genome hybridization, which
were all negative. Clinical trio-based WES of Family 1 and WGS
of the Israeli probands and their parents (Family 2) were per-
formed as previously described.9,10 Immortalized lymphoblastoid
cell lines were used for RNA extraction, reverse transcription
polymerase chain reaction (RT-PCR) analysis, and semiquantita-
tive RT-PCR assay. Sanger sequencing was performed to analyze
segregation of the variants identified by WES/WGS.
Vamp1lew/lew Mice
Breeder pairs of Vamp11/lew mice (C3H/HeDiSnJ-Vamp1lew/GrsrJ,
stock # 004626) were obtained from the Jackson Laboratory
(Bar Harbor, ME) and mated to generate homozygous mutant
(Vamp1lew/lew) mice. Electrophysiological and morphological anal-
yses of the NMJ in the Vamp1lew/lew mice were performed as previ-
ously reported.11,12 All experimental protocols were approved by
the University of Texas Southwestern Medical Center institutional
animal care and use committee.
Results
Clinical and Neurophysiological Characteristics
FAMILY 1. Both affected individuals A.II-1 and A.II-3
(Fig 1A) presented shortly after birth with hypotonia and
muscular weakness. Feeding difficulties requiring gavage
feeding, delayed motor development, and ophthalmopa-
resis characterized the disease course. A.II-3 also pre-
sented joint contractures. Creatine kinase and plasma lac-
tate were normal in the 2 children. On initial evaluation
of Patient A.II-3, muscle biopsy showed myopathic fea-
tures and borderline low complex IV activity (0.011; nor-
mal range5 0.014–0.034), but congenital myopathy
gene panel and mtDNA analysis were negative. Although
hypotonia slightly improved in Patient A.II-1, at the age
of 3 years she still had difficulties standing upright and
was unable to walk without support. Electrodiagnostic
examination (EDX) in the 2 individuals showed similar
findings (Table), with marked reduction in the amplitude
of the compound muscle action potentials (CMAPs) and
an increase in the amplitude to >200% of baseline on
repetitive nerve stimulation (RNS) to 20Hz, indicating
presynaptic impairment of NMJ transmission. The child-
ren’s weakness slightly ameliorated under pyridostigmine
treatment.
FAMILY 2. The affected individuals of this family
(B.II-2 and B.II-3; see Fig 1B) showed severe hypotonia
and muscle weakness since birth. Both siblings had
feeding difficulties and required percutaneous endoscopic
gastrostomy. They presented severe impairment of devel-
opmental milestones. B.II-1 also showed joint laxity and
kyphoscoliosis. B.II-3 presented knee contractures and
breathing difficulties. During disease course, both chil-
dren showed markedly reduced ability to generate anti-
gravity posture and movements. B.II-2 never reached
autonomous walk; his EDX showed severely low CMAPs
and increased neuromuscular jitter, indicating NMJ trans-
mission abnormalities (see Table 1). In both siblings, pyri-
dostigmine treatment improved symptoms.
Identification of the VAMP1 Mutation
Trio-based WES of Family 1 (A.I-1, A.I-2, A.II-1; see
Fig 1A) indicated in the index case 3 genes (Supplemen-
tary Table 1) carrying homozygous exonic variants pre-
dicted to have a possible pathogenic effect on protein
function, based on the guidelines for variant classifica-
tion.13 Full Sanger-based segregation analysis of the can-
didate variants reduced the gene list to only 1 mutation
in VAMP1 (NM_014231: c.51_64delAGGTGGGG
GTCCCC; p.Gly18TrpfsTer5*), which was found to be
homozygous in the affected individuals and heterozygous
in their healthy sister and in the unaffected parents
(see Fig 1C; data shown for the index case and her
parents).
WGS of the 4 members of Family 2 (B.I-2, B.I-
3, B.II-2, B.II-3; see Fig 1B) identified 6 genes carry-
ing rare (likely) damaging variants (Supplementary
Table 2), which were homozygous in the affected indi-
viduals and heterozygous in the parents.12 Among
these 6 variants, a homozygous missense mutation in
VAMP1 (NM_014231: c.146G>C; p.Arg49Pro; see
Fig 1D) emerged as the most likely explanation for
the disease pathogenesis, as supported by protein func-
tion (the mutation affects a conserved amino acid
within the active domain of the protein),14,15 expres-
sion and role of this gene in the NMJ,12,16 and the
homozygous mutation identified in the patients
from Family 1 presenting the same phenotype (see
Fig 1C–G).
RT-PCR assay (performed to analyze possible
nonsense-mediated decay associated with the VAMP1
truncating variant in Family 1) found a mild reduction
of mutant cDNA expression in the index case compared
to the heterozygous carriers and the wild-type control
(see Fig 1E, F).
Impairments of the Neuromuscular Junction in
Vamp1lew/lew Mice
To further investigate whether a biallelic null mutation in
VAMP1 in animal models may cause presynaptic NMJ
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FIGURE 1: Family trees, Sanger sequencing, and VAMP1 mutation analysis. (A) Pedigree from Family 1. (B) Pedigree from Fam-
ily 2. (C) Electropherograms of carrier parents and index case with the c.51_64delAGGTGGGGGTCCCC variant. (D) Electro-
pherograms of carrier parents and the 2 patients with the c.146G>C variant. (E) Reverse transcription polymerase chain
reaction (PCR) amplifying the mutant cDNA transcript from mRNA extracted from the immortalized lymphoblastoid cell lines of
the index case, her father, and her healthy sister (both carriers of the heterozygous deletion), and a wild-type control (CTRL).
(F) Analysis of the semiquantitative PCR using the densitometry software ImageJ after normalization relative to a housekeep-
ing gene (GAPDH) and calculation using a relative relationship method. (G) Multiple-sequence alignment showing complete
conservation of protein sequence across species and SNARE homolog VAMP2 in the v-SNARE coiled coil homology, in which
the disease-segregating mutation p.Arg49Pro was found. (H) VAMP1 protein representative. The c.51_
64delAGGTGGGGGTCCCC deletion causes a nonsense mutation, putatively producing a truncated protein lacking the v-SNARE
and the transmembrane (TM) domains, whereas the p.Arg49Pro mutation affects an active site of the conserved v-SNARE
domain.
abnormalities similarly to affected individuals, we re-
examined Vamp1lew/lew mutant mice that were previously
described.11,12 The endplates were localized along the cen-
tral regions of the muscle in both control and Vamp1lew/lew
mice (Fig 2). Individual neuromuscular synapses were
found markedly smaller in Vamp1lew/lew mice compared
with control, and a severe reduction in endplate potentials
(EPPs) was also observed in the mutant mice. Importantly,
a low-frequency, repetitive stimulation (10Hz) led to a
run-down of EPPs in control mice, but synaptic facilita-
tion in Vamp1lew/lew mice, indicating presynaptic defects.
Discussion
Here, we report 4 children from 2 consanguineous
families who presented with typical clinical and neuro-
physiological features of presynaptic CMS associated
with homozygous mutations in VAMP1.
The protein encoded by this gene is a member
of the synaptobrevin family.14 Synaptobrevins (eg,
Vamp1, Vamp2), syntaxins, and the synaptosomal-
associated protein Snap25 represent the main compo-
nents of the SNARE (soluble N -ethylmaleimide-
sensitive factor attachment protein receptors) complex,
which is involved in docking and fusion of synaptic
vesicles with the presynaptic membrane at the central
and the neuromuscular synapses.15,16 Proteins belonging
to this complex are involved in vesicle docking through
the evolutionarily conserved active v-SNARE coiled coil
homology domain and present high sequence similarity
across the different SNAREs.17–19
Notably, the c.51_64delAGGTGGGGGTCCCC
frameshift deletion identified in Family 1 leads to a
change in the gene reading frame with the generation of
a premature stop codon 5 amino acids downstream
(see Fig 1H). The result is a putative VAMP1 product of
only 21 amino acids, with a resulting function that is
highly likely to be disrupted due to the absence of the
downstream v-SNARE domain (amino acids 33–93). The
TABLE 1. Clinical and Neurophysiological Features of VAMP1-Associated Congenital Myasthenic Syndrome in
Our Families
Feature A.II-1 A.II-3 B.II-1 B.II-2
Parental consanguinity 1 1 1 1
Onset Birth Birth Antenatal, DFM Birth
Muscle weakness 11 11 11 11
Developmental delay 11 11 11 11
Feeding difficulties 11 11 11 11
Ophthalmological
abnormalities
Strabismus,
mild ophthalmoplegia
Mild
ophthalmoplegia
Strabismus Strabismus
GI abnormalities 2 GERD Dysphagia Dysphagia
Skeletal joint abnormalities 2 Joint
contractures
Joint laxity,
kyphoscoliosis
Joint
contractures
Chest infections, aspiration 1 1 1 1
Response to pyridostigmine 1 1 1 1
Sensory studies Normal Normal Normal NT
Motor studies AH CMAP ## AH CMAP ## ACL CMAP ## NT
EMG Myopathic Myopathic Myopathic NT
Repetitive stimulation AH: 3Hz,1 32.8%;
20Hz,1 640%
AH: 3Hz,1 60%;
20Hz,1 207%
NA NT
Jitter EDC, no twitch Orb oculi, no twitch "" mean MCD5 74.3ms NT
ACL5 accessorius motor left; AH5 abductor pollicis; CMAP5 compound muscle action potential; DFM5decreased fetal movements;
EDC5 extensor digitorum communis; EMG5 electromyogram; GERD5 gastroesophageal reflux disease; GI5 gastrointestinal; MCD5mean
consecutive difference; NA5 not available; NT5 not tested; Orb oculi5 orbicularis oculi.
ANNALS of Neurology
600 Volume 81, No. 4
homozygous mutation identified in Family 2 consists of a
substitution of a highly conserved arginine (Gerp11
score5 5.77) by a proline within the v-SNARE domain.
The mutated arginine residue in position 49 corresponds
to the arginine in position 47 of the better-studied
SNARE homolog VAMP2, encoding another synaptobre-
vin with similar functions to VAMP1.20
Interestingly, it has been shown that disruption of
this specific site in VAMP2 interferes with SNARE com-
plex assembly, impairing neurotransmission, likely due to
lack of association with other proteins involved in vesicle
fusion.21–23 The Arg49Pro mutation is predicted as dele-
terious by SIFT, PolyPhen, and Mutation Taster and is
carried in the heterozygous state by only 1 individual in
the ExAC database (http://exac.broadinstitute.org, last
accessed January 2017). Of note, in the ExAC database
of 60,706 individuals there are only 17 individuals with
heterozygous nonsynonymous single nucleotide substitu-
tions within the v-SNARE domain and 4 individuals in
total carrying heterozygous truncating variants in
VAMP1. None of these variants is present as homozy-
gous, providing supportive evidence of pathogenicity for
FIGURE 2: Synaptic defects at the neuromuscular junctions in Vamp1lew/lew mice. (A, B) Low-power images of the whole-mount
diaphragm muscles (P14) labeled by Texas Red—conjugated a-bungarotoxin. The endplate band (arrow) is similarly localized
along the central regions of the muscle in both control (A) and Vamp1lew/lew mice (B). (C–H) High-power confocal images of
individual neuromuscular synapses in triangularis sterni muscles, labeled by Texas Red–conjugated a-bungarotoxin (arrowheads
in C and F) and antineurofilament NF150 and antisynaptotagmin2 antibodies (arrowheads in D and G point to the nerve termi-
nals). Merged images are shown in E and H, for control and Vamp1lew/lew mice, respectively. (I, J) Individual neuromuscular syn-
apses (arrows) in triangularis sterni muscles labeled by antisyntaxin1 antibodies. The synapses are markedly smaller in
Vamp1lew/lew mice compared with the control. Asterisks indicate nerve bundles. (K) An example of endplate potentials (EPPs)
recorded in the diaphragm muscle in control and Vamp1lew/lew mice. (L) EPP traces responding to a low-frequency, repetitive
nerve stimulation (10Hz). (M) Quantitative measurement of the ratios of EPP amplitudes: EPP(n) to the first EPP amplitude,
(EPP1). A low-frequency, repetitive stimulation (10Hz) led to a run-down of EPPs in control, but synaptic facilitation in
(Vamp1lew/lew) mice.
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biallelic VAMP1 variants, either resulting in changes of
the gene reading frame or affecting conserved active sites
crucial to v-SNARE domain function.
Interestingly, we also showed that the electrodiag-
nostic anomalies recorded in VAMP1-associated CMS are
consistent with the abnormal features of presynaptic
transmission we recorded in the VAMP1 null mutant
mice (including the incremental response to RNS; see
Fig 2). These animals, of a model called lethal wasting
(carrying a homozygous mutation that causes the trunca-
tion of half of the protein), lack movement because of an
impaired NMJ transmission and die within 3 weeks of
birth.11,12
To date, biallelic variants in VAMP1 have never
been reported, but heterozygous mutations in this gene
have been described by a single study in association with
a phenotype of autosomal dominant spastic ataxia.23
However, we have not observed any neurological pheno-
type in the heterozygous carriers from the 2 families.
In conclusion, the identification of biallelic variants
in VAMP1 as a novel cause of CMS, in addition to other
genes (eg, SNAP25B, SYT2) previously associated with
similar presynaptic abnormalities of neuromuscular trans-
mission,5,6 highlights the crucial role of different
SNAREs in NMJ physiology. Intriguingly, the relatively
mild phenotype showed by our patients compared to the
mouse model, which dies prematurely, suggests the possi-
ble existence of species-specific compensation of vesicle
fusion and release at the nerve terminal, perhaps through
genetic modifiers in humans but not in mice or fruit
flies. This highlights a promising area of future research
aimed at the pathways involved in physiological presyn-
aptic vesicle exocytosis at the motor endplate.
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